ABION to Participate in BioEurope... "Presentation of Pipeline and Key R&D Achievements"

Abion announced on the 28th that it will participate in the '2024 BIO-Europe Fall' to be held in Stockholm, Sweden from the 4th to the 6th of next month.

Selected as a presenting company, Abion will focus on its pipeline products ABN202 and ABN501. In addition, it plans to introduce major research and development (R&D) achievements and conduct business development (BD) partnering with multinational pharmaceutical and biotech companies as well as academic researchers.

The Antibody Cytokine Fusion Protein (ACFP) platform ABN202, which fuses interferon-beta variants with tumor-targeting antibodies, demonstrated excellent anticancer effects in various solid tumor preclinical models. ACFP is gaining attention as a new therapeutic strategy that overcomes resistance mechanisms of conventional antibody-drug conjugates (ADC).

Abion will also introduce ABN501, the world's only claudin-3 targeting antibody therapeutic. ABN501 is currently under joint research based on a research and development partnership with the National Cancer Institute (NCI) under the U.S. National Institutes of Health (NIH).

A company representative stated, "We will explore collaboration possibilities through one-on-one partnering with industry stakeholders and institutional investors to strengthen our position in the global market," adding, "We will strive to generate various achievements at the event."

Meanwhile, BIO-Europe is the world's largest biotech partnering event. Through the Partnering ONE platform, companies and representatives from over 60 countries can hold one-on-one meetings. This year, more than 5,000 potential partners are expected to participate, with licensing deals, investment attraction, and global networking anticipated.

This content was produced with the assistance of AI translation services.